Company intelligence / Profile preview

Virogen Biotechnology

Pleasanton, California, United Statesinformaconnect.com ↗
Ownership
Private
Development stage
Other
01

Overview

VG712 has demonstrated promising safety and efficacy in a completed Phase 1 trial for cutaneous T-cell lymphoma. The drug shows rapid, transient depletion of all T cell subtypes without triggering cytokine release syndrome or toxicity to other immune cells. It is more efficacious than standard agents like alemtuzumab or rATG at clearing T cells from blood, skin, and lymph nodes with minimal adverse effects. A pivotal Phase 2 trial is ongoing with plans to expand into additional indications including use as a lymphodepletion agent prior to adoptive cell therapies such as CAR-T.

Therapeutic areas
ImmunologyOncology
Modalities
Antibody toxin conjugate ("immunotoxin")Fusion protein therapy
Industry
Biotech
02

Drug pipeline

2 assets

Innovo Immune Newcastle Vaccine

Unknown

1 more asset in the full pipeline.

Request access →
03

Partnerships

Moffitt Cancer Center — strategic partnership focused on accelerating development of VG712 across oncology/immunotherapy applications.WuXi Biologics — contract manufacturing partner providing process validation and commercial-scale production services for VG712 using microbial fermentation platforms.

Beyond the preview

Go deeper on Virogen Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Virogen Biotechnology.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call